- Previous Close
210.23 - Open
209.61 - Bid 207.00 x 800
- Ask 212.50 x 900
- Day's Range
207.95 - 212.69 - 52 Week Range
196.80 - 281.70 - Volume
4,877,647 - Avg. Volume
3,991,162 - Market Cap (intraday)
150.904B - Beta (5Y Monthly) 0.86
- PE Ratio (TTM)
39.84 - EPS (TTM)
5.30 - Earnings Date Apr 21, 2025 - Apr 25, 2025
- Forward Dividend & Yield 1.08 (0.51%)
- Ex-Dividend Date Dec 27, 2024
- 1y Target Est
267.38
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
www.danaher.com61,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: DHR
View MorePerformance Overview: DHR
Trailing total returns as of 2/24/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DHR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DHR
View MoreValuation Measures
Market Cap
150.90B
Enterprise Value
165.97B
Trailing P/E
39.91
Forward P/E
27.78
PEG Ratio (5yr expected)
3.97
Price/Sales (ttm)
6.52
Price/Book (mrq)
3.05
Enterprise Value/Revenue
6.95
Enterprise Value/EBITDA
22.81
Financial Highlights
Profitability and Income Statement
Profit Margin
16.33%
Return on Assets (ttm)
4.02%
Return on Equity (ttm)
7.57%
Revenue (ttm)
23.88B
Net Income Avi to Common (ttm)
3.9B
Diluted EPS (ttm)
5.30
Balance Sheet and Cash Flow
Total Cash (mrq)
2.08B
Total Debt/Equity (mrq)
34.60%
Levered Free Cash Flow (ttm)
4.71B